Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC

GENELUX Corp

Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.
FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.
Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.